Early Activation of an Altered Thyroid Hormone Profile in Asymptomatic or Mildly Symptomatic Idiopathic Left Ventricular Dysfunction

Journal of Cardiac Failure

Volumn 12, Issue 7, 2006, Pages 520-526

  Pingitore, Alessandro ^a   Iervasi, Giorgio ^a   Barison, Andrea ^a   Prontera, Concetta ^a   Pratali, Lorenza ^a   Emdin, Michele ^a   Giannessi, Daniela ^a   Neglia, Danilo ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Idiopathic cardiomyopathy; Natriuretic peptides; Thyroid

Indexed keywords

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; INTERLEUKIN 6; LIOTHYRONINE; NORADRENALIN; RENIN; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CORRELATION ANALYSIS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; UNIVARIATE ANALYSIS;

AGED; CARDIAC OUTPUT, LOW; FEMALE; HORMONES; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; NEUROSECRETORY SYSTEMS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; THYROID GLAND; THYROID HORMONES; TRIIODOTHYRONINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33748101391     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.05.009     Document Type: Article

References (32)

1. Manowitz N.R., Mayor G.H., Klepper M.J., and DeGroot L.J. Hypothyroidism and thyroid sick syndrome in patients with moderate to severe congestive heart failure. Am J Ther 3 (1996) 797-801
2. Hamilton M.A., Stevenson L.W., Luu M., and Walden J.A. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol 16 (1990) 91-95
3. Pingitore A., Landi P., Taddei M.C., Ripoli A., L'Abbate A., and Iervasi G. Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am J Med 118 (2005) 132-136
4. Kozdag G., Ural D., Vural A., et al. Relation between free triiodothyronine/free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy. Eur J Heart Failure 7 (2005) 113-118
5. Ascheim D.D., and Hryniewicz K. Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state. Thyroid 12 (2002) 511-515
6. Iervasi G., Pingitore A., Landi P., et al. Low T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 107 (2003) 708-713
7. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 (1984) 819-823
8. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the 9. Studies of left ventricular dysfunction (SOLVD). Circulation 82 (1990) 1724-1729
9. Mann D.L. Mechanism and model in heart failure. Circulation 100 (1999) 999-1008
10. Koglin J., Pehlivanli S., Schwaiblmair M., Vogeser M., Cremer P., and VonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38 (2001) 1934-1941
11. Opie L.H. Cellular basis for therapeutic choices in heart failure. Circulation 110 (2004) 2559-2561
12. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 77 (1998) 721-730
13. Boelen A., Platvoet-ter S.M., Schiphorst M.C., and Wiersinga W.M. Association between serum interleukin-6 and serum 3, 5, 3′-triiodothyronin in nonthyroidal illness. J Clin Endocrinol Metab 77 (1993) 1695-1699
14. Boelen A., Maas M.A., Lowik C.W., Platvoet-ter S.M., and Wiersinga W.M. Induced illness in interleukin-6 (IL-6) knock-out mice: a casual role of IL-6 in the development of the low 3, 5, 3′-triiodothyronine syndrome. Endocrinology 137 (1996) 5250-5254
15. Boelen A., Kwakkel J., Platvoet-ter S.M., Baur A., Kohrle J., and Wiersinga W.M. Contribution of interleukin-12 to the pathogenesis of non-thyroidal illness. Horm Metab Res 36 (2004) 101-106
16. Klein I., and Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 344 (2001) 501-509
17. Kahaly G.J., and Dillmann W.H. Thyroid hormone action in the heart. Endocr Rev 6 (2005) 704-728
18. Sabatino L., Colantuoni A., and Iervasi G. Is the vascular system a main target for thyroid hormones? From molecular and biochemical findings to clinical perspectives. Curr Vasc Pharmacol 3 (2005) 133-145
19. Neglia D., Michelassi C., Trivieri M.G., et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 15 (2002) 186-193
20. Emdin M., Passino C., Prontera C., et al. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 42 (2004) 627-636
21. Iervasi G., Emdin M., Colzani R.M.P., et al. Beneficial effects of long-term triiodothyronine (T3) infusion in patients with advanced heart failure and low T3 syndrome. In: Kimchi A. (Ed). Heart disease: new trends in research, diagnosis and treatment (2001), Medimont, Englewood (NJ) 549-553
22. Moruzzi P., Doria E., and Agostoni P.G. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med 101 (1996) 461-467
23. Hamilton M.A., Stevenson L.W., and Fonarow G.C. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol 81 (1998) 443-447
24. Pingitore A., and Iervasi G. Thyroid (dys)function in heart failure: is it a potential target for medical treatment?. Vascular Health Risk Manage 1 (2005) 97-100
25. Zoccali C., Tripepi G., Cutrupi S., Pizzini P., and Mallamaci F. Low triiodothyronine: a new facet of inflammation in end-stage renal disease. J Am Soc Nephrol 16 (2005) 2789-2795
26. Colantuoni A., Marchiafava P.L., Lapi D., Forini F.S., and Iervasi G. Effects of tetraiodothyronine and triiodothyronine on hamster cheek pouch microcirculation. Am J Physiol Heart Circ Physiol 288 (2005) H1931-H1936
27. Trivieri M.G., Oudit G.Y., Sah R., et al. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci U S A 11 103 (2006) 6043-6048
28. Khalife W.I., Tang Y., Kuzman J.A., et al. Treatment of sub-clinical hypothyroidism reverses ischemia and prevents myocyte loss and progressive LV dysfunction in hamsters with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289 (2005) H2409-H2415
29. Wassen F.W., Schiel A.E., Kuiper G.G., et al. Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology 143 (2002) 2812-2815
30. Scanlan T.S., Suchland K.L., Hart M.E., et al. 3-iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 10 (2004) 638-642
31. Wu S.Y., Green W.L., Huang W.S., Hays M.T., and Chopra I.J. Alternate pathways of thyroid hormone metabolism. Thyroid 15 (2005) 943-958
32. Tang Y.D., Kuzman J.A., Said S., Anderson B.E., Wang X., and Gerdes A.M. Low thyroid function leads to cardiac atrophy with chamber dilatation, impaired myocardial blood flow, loss of arterioles, and severe systolic dysfunction. Circulation 112 (2005) 3122-3130